Optimism For Biopharma In 2025
By Tyler Menichiello, Chief Editor, Bioprocess Online
Despite negative headlines and geopolitical uncertainty, there are plenty of reasons to be optimistic heading into 2025, including market approvals, clinical data, and the continuous emergence of innovative technologies, products, and companies. In this closing segment from “Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond,” CEO, co-founder, and president of Ossium Health, Kevin Caldwell; CSO of FibroBiologics, Hamid Khoja, Ph.D.; and president and acting CEO of Triumvira Immunologics, Rob Williamson, express confidence in the mission and maintain a positive outlook for the years ahead.